Latest Breaking News On - Niyad commercialisation timeline - Page 1 : comparemela.com

Without knowledge of the DSUVIA deal it is hard to assess the prospect, so I retain a neutral rating with a tilt to buy. Read more about ACRX stock here.

South koreaUnited statesVadzim kushniarouEin geschB das konzeptNafamostat niyadVincent angottiNiyad nafamostatClinical development of niyadDepartment of anesthesiologyDivision of renal diseasesAscs ambulatory surgical centersGeorge washington universityAcelrx pharmaceuticals incLowell therapeutics incUs army